Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

05 mai 2022 16h05 HE | Source: Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals Provides Corporate Update and Reports First Quarter 2022 Financial Results

Phase 1 data for LP352, a potential treatment for seizures associated with a broad range of severe epilepsies, presented at the American Academy of Neurology (AAN) Annual MeetingInitiated Phase 1b/2a...
03 mars 2022 16h05 HE | Source: Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals Provides Corporate Update and Reports Full Year 2021 Financial Results

Initiated the Phase 1b/2a PACIFIC Study, evaluating LP352 in participants with developmental and epileptic encephalopathies (DEEs)LP352 demonstrated statistically significant reduction of epileptiform...
04 nov. 2021 16h05 HE | Source: Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2021 Financial Results

Successfully completed multiple ascending dose (MAD) portion of a Phase 1 clinical trial for LP352, a potential treatment for seizures associated with a broad range of severe epilepsiesInitiating a...
10 mai 2021 16h05 HE | Source: Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals Provides Corporate Update and Reports First Quarter 2021 Financial Results

Commenced multiple ascending dose (MAD) portion of the Phase 1 study for LP352, a potential treatment for severe epileptic indications; topline results expected in the second half of 2021 ...